Rhinomed is pleased to provide its report for the half year ended 31 December 2020.
Commenting on the results, Rhinomed’s CEO Michael Johnson said “2020 produced unheralded uncertainty in all of our major markets, despite this Rhinomed continued its strong focus on delivering value to our customers, clinicians and retail partners right across the world. Our unique product range which includes the Turbine, Mute and Pronto vapour delivery platform continues to help people to breathe and sleep better. By working closely with our clinician and retail partners we were able to minimise supply chain disruption and consistently deliver.